New antibiotic tackles tough infections in vulnerable patients
NCT ID NCT04673175
First seen Jan 28, 2026 · Last updated Apr 30, 2026 · Updated 14 times
Summary
This study looked at whether the antibiotic ceftolozane-tazobactam can treat serious Pseudomonas infections in people with blood cancers or who had a stem cell transplant. Participants received the drug through a vein for 10 to 14 days. Researchers tracked survival and infection clearance at 30 and 60 days. The study was stopped early, but results may still help guide treatment for these high-risk patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.